We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
08 Dec 23
First global Phase 3 study to report positive results with an anti-CD38 therapy in combination with VRd in…
08 Dec 23
The agreement allows for ArteraAI and GenesisCare to collaborate in Australia to generate real-world data on AI tools…
07 Dec 23
IGC Pharma to Discuss AI Partnership and Initiatives at Biotech Showcase 2024
06 Dec 23
A comparison of the intent-to-treat population at eight years of follow-up with MONARCH 3 revealed that women taking…
06 Dec 23
The trial achieved progression-free survival (PFS) and showed a statistically significant and clinically meaningful improvement against palbociclib and…
04 Dec 23
ARDENT is a Phase 1 study evaluating safety and tolerability of SC291 in patients with CLL and non-Hodgkin…
01 Dec 23
In the study, etrasimod treatment produced a clinically meaningful and statistically significant improvement in primary endpoint as well…
01 Dec 23
The Phase 1 open-label trial studied the delivery of QN-01 via the RespiRx device for three different nicotine…
29 Nov 23
V116 is an investigational, 21-valent vaccine, currently in late-stage trial for prevention of invasive pneumococcal disease and pneumococcal…
28 Nov 23
In the trial, Dupixent reduced moderate or severe acute COPD exacerbations by 34% over 52 weeks and led…